Jonathan Hodgson


A foolish consistency is the hobgoblin of little minds - Ralph Waldo Emerson

Jonathan is a leader in Putnam’s New Products Strategy practice, and Pricing, Reimbursement & Market Access practice, bringing more than 10 years of experience helping biopharmaceutical companies make better strategic decisions. He has worked with clients on commercialization strategy, R&D strategy, portfolio planning, launch pricing and reimbursement, forecasting, asset valuation and other custom assignments across a broad range of therapeutic areas. He brings particularly deep expertise in leveraging innovative methodologies and large data sets to support analysis and decision-making. Prior to joining Putnam, Jonathan worked as a strategy consultant at L.E.K. and the Amundsen Group. Before his consulting career, Jonathan served in several roles at Vertex Pharmaceuticals. Jonathan is co-author of “Biopharma: Beyond the First Product,” published in In Vivo, and has lectured on valuation approaches and techniques at the Mass Biotech Council. Jonathan received undergraduate degrees at Dartmouth College and an MBA from Harvard Business School.

Strategy for the Life Sciences